PRI-724
As of the edition of 20 October 2026, PRI-724 is a drug: in active development; acts on CREBBP and CTNNB1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2024
- Kind
- Unknown
- Registered trials
- 11, 2 stopped early
- Disease areas
- Digestive system; Blood and lymph; Cancer; Inherited and neonatal; Hormones; Infections
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 1 | 0 | 0 |
| Phase 1 | 5 | 4 | 0 | 1 |
| Phase 2 | 5 | 3 | 1 | 1 |
| All trials | 11 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Prism Pharma | Lead sponsor of trials | 2011 to now |